1. Home
  2. FEMY vs DXR Comparison

FEMY vs DXR Comparison

Compare FEMY & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.82

Market Cap

51.5M

Sector

Health Care

ML Signal

HOLD

Logo Daxor Corporation

DXR

Daxor Corporation

HOLD

Current Price

$12.87

Market Cap

61.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEMY
DXR
Founded
2004
1970
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.5M
61.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
FEMY
DXR
Price
$0.82
$12.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$6.83
$25.00
AVG Volume (30 Days)
1.4M
2.7K
Earning Date
11-14-2025
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.46
EPS
N/A
0.36
Revenue
$2,061,502.00
$66,306.00
Revenue This Year
$64.02
N/A
Revenue Next Year
$147.19
N/A
P/E Ratio
N/A
$35.00
Revenue Growth
63.53
N/A
52 Week Low
$0.31
$6.55
52 Week High
$1.80
$14.15

Technical Indicators

Market Signals
Indicator
FEMY
DXR
Relative Strength Index (RSI) 47.72 47.99
Support Level $0.79 $12.38
Resistance Level $0.89 $12.90
Average True Range (ATR) 0.07 0.25
MACD -0.01 -0.01
Stochastic Oscillator 26.39 38.39

Price Performance

Historical Comparison
FEMY
DXR

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

About DXR Daxor Corporation

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

Share on Social Networks: